Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEKAMLO is an oral tablet small-molecule NDA approved by Novartis in August 2010. The specific mechanism of action and therapeutic indications are not publicly detailed in available data, limiting characterization of its clinical role. As a formulation-based product, it likely represents a combination or optimized delivery approach within its therapeutic area.
Peak3.1 years to LOE
Product is at peak commercial maturity with high competitive pressure (score: 8/10), indicating mature market positioning and likely stable but defended revenue streams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on TEKAMLO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.